ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANIP leans into rare disease growth as Cortrophin and Iluvien drive specialty momentum, while 2026 focuses on retina recovery and launch cadence.
ANIP - ANI Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$124.00
DETAILS
HIGH:
$124.00
LOW:
$124.00
MEDIAN:
$124.00
CONSENSUS:
$124.00
UPSIDE:
49.90%
Stock News
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANI Pharmaceuticals trades at 9.83x forward earnings, far below peers and its five-year median despite rising Rare Disease sales.
ANIP Stock: What's Driving Cortrophin Gel's 2026 Surge
Cortrophin Gel is reshaping ANI Pharmaceuticals into a specialty-driven growth story, with 2026 revenue guidance signaling another major leap.
ANI Pharmaceuticals (ANIP) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets.
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
ANI Pharmaceuticals tops Q1 estimates as Cortrophin Gel sales climb 42%, prompting it to raise the 2026 revenue, EBITDA and EPS outlook.
ANI Pharmaceuticals Q1 Earnings Call Highlights
ANI Pharmaceuticals NASDAQ: ANIP reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease company,” led by growth in Cortrophin Gel and ILUVIEN, contributions from a new intellectual property licensing transaction with Harmony Biosciences, and steady generics performance.
ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript
ANI (ANIP) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.05 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.7 per share a year ago.
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended March 31, 2026.
ANI Pharmaceuticals (ANIP) is a Top-Ranked Growth Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are These 5 Biotech Stocks Set to Beat Q1 Earnings Estimates?
ANI Pharmaceuticals, Novavax and three other biotechs show strong Earnings ESP signals, hinting at potential Q1 earnings beat as sector results roll in.
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Should You Buy?
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
Why ANI (ANIP) is Poised to Beat Earnings Estimates Again
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's Why ANI Pharmaceuticals (ANIP) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open.
Price Targets
ANI Pharmaceuticals (ANIP) PT Raised to $124 at Guggenheim
$124.00
(was $85.29)
Vamil Divan
·
Guggenheim
ANI Pharmaceuticals price target raised to $90 from $77 at Truist
$90.00
(was $91.63)
Truist Financial
ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright
$121.00
(was $95.36)
Brandon Folkes
·
H.C. Wainwright
ANI Pharmaceuticals price target raised to $114 from $86 at Guggenheim
$114.00
(was $95.20)
Vamil Divan
·
Guggenheim
ANI Pharmaceuticals price target raised to $94 from $80 at Piper Sandler
$94.00
(was $81.13)
David Amsellem
·
Piper Sandler
ANI Pharmaceuticals price target raised to $86 from $84 at Guggenheim
$86.00
(was $59.68)
Guggenheim
ANI Pharmaceuticals price target raised to $83 from $81 at Raymond James
$83.00
(was $61.23)
Gary Nachman
·
Raymond James
ANI Pharmaceuticals downgraded to Hold from Buy at Truist
$60.00
(was $55.48)
Les Sulewski
·
Truist Financial
ANI Pharmaceuticals (ANIP) PT Raised to $94 at H.C. Wainwright
$94.00
(was $65.49)
Oren Livnat
·
H.C. Wainwright
ANI Pharmaceuticals (ANIP) PT Raised to $87 at H.C. Wainwright
$87.00
(was $68.06)
Oren Livnat
·
H.C. Wainwright
Raymond James Maintains Outperform on ANI Pharmaceuticals, Raises Price Target to $48
$48.00
(was $34.87)
Raymond James